A Pilot Study of Triple NtRTI/NsRTI Therapy in Antiretroviral Naive HIV-1 Infected Patients

Inclusion Criteria: * 18 years and older * HIV-1 positive * antiretroviral treatment naive * one CD4 count \>200/ul within 14d prior to study drug administration * one HIV-1 RNA PCR value \>5000 and \<100.000 cop/ml within 14d prior to study drug administration * women of child bearing potential: negative serum pregnancy test within 14d of study * ability to understand and provide written informed consent * overall stable disease * absence of clinical signs of lipodystrophy Exclusion Criteria: * alcohol or illicit drug use * malabsorption syndrome or other gastrointestinal dysfunction * clinically relevant pancreatitis/hepatitis within the last 6 months * receiving other investigational drugs * abnormal hemoglobin, neutrophil, platelet, AST/ALT, pancreatic amylase, creatinine clearance, total bilirubine levels within 14d prior to study * pregnancy/breast-feeding * radiation therapy or cytotoxic chemotherapeutic agents within 30d of study * prior antiretroviral therapy at any time, investigational antiretrovirals trial at any time, HIV vaccine within 90d prior to study * immunomodulating agents * serious medical condition (diabetes, congestive heart failure, cardiomyopathy, or other cardiac dysfunction) * active diagnosis of AIDS (except for cutaneous Kaposi Sarcoma) * foscarnet therapy or other agent with documented activity against HIV-1